Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascendis Pharma A/S (ASND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Ascendis files annual reports on Form 20-F and furnishes interim updates on Form 6-K, which include clinical, regulatory, financial, and corporate information related to its TransCon-based therapies.
In these filings, investors can review details on Ascendis’ pharmaceutical preparation manufacturing activities, including revenue from commercial products such as YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency. Unaudited condensed consolidated interim financial statements, management’s discussion and analysis, and segment information by geography (North America, Europe, and rest of world) are typically included in quarterly 6-K submissions.
Filings also describe the status of key pipeline programs like TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in oncology, along with updates on regulatory reviews by the U.S. Food and Drug Administration and the European Medicines Agency. Additional 6-Ks may cover warrant grants, share capital changes, and the operation of equity compensation plans and share repurchase programs.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy 20-F and 6-K filings, helping users quickly understand revenue drivers, operating results, and key clinical or regulatory events. Real-time updates from EDGAR ensure that new Ascendis filings, including financial statements and other material disclosures, are available promptly, while structured access makes it easier to locate specific reports relevant to ASND analysis.
Ascendis Pharma A/S reported the results of its Annual General Meeting, where shareholders representing 56,234,042 ordinary shares, or 90.16% of shares outstanding, were present or represented. All agenda items were approved with strong support across the ballot.
Shareholders adopted the audited annual report for the year ended December 31, 2025 and discharged the Board of Directors and management from liability. They also approved carrying forward the consolidated loss of EUR 228 million for 2025 into 2026 via accumulated deficit.
All incumbent Board members were re-elected and Jean-Jacques Bienaimé joined as a new non-executive director, with terms running until the 2027 annual meeting. Shareholders also renewed authority allowing the Board, until March 22, 2031, to repurchase up to nominal DKK 1,000,000 of shares or equivalent American Depositary Shares as treasury shares.
Ascendis Pharma A/S director William Fairey has filed an initial ownership report outlining his equity position in the company. The filing shows direct ownership of 2,117 Ordinary Shares, as well as warrants over 9,160 Ordinary Shares with an exercise price of $102.7000 per share that expire on September 13, 2032.
He also holds several grants of Restricted Stock Units representing 1,374, 2,070 and 1,930 underlying Ordinary Shares. Each restricted stock unit represents a contingent right to receive one American Depositary Share, and each ADS represents one Ordinary Share. The footnotes state that these RSUs vest on or beginning on March 1, 2027 under different installment schedules.
Ascendis Pharma A/S director Imani Siham has filed an initial ownership report showing equity and equity-linked holdings in the company. The filing lists 2,317 Ordinary Shares held directly. It also shows warrants over 9,160 Ordinary Shares with an exercise price of $102.70 per share, expiring on September 13, 2032.
In addition, Siham holds several grants of restricted stock units, each representing a contingent right to receive one American Depositary Share, which in turn represents one Ordinary Share. According to the footnotes, these restricted stock units vest on March 1, 2027 or in two or three equal annual installments beginning on that date and have no expiration date.
Ascendis Pharma A/S executive vice president and chief financial officer Scott Thomas Smith filed an initial statement of ownership showing a mix of direct equity and derivative awards linked to the company’s ordinary shares and American Depositary Shares.
He holds warrants over 45,000 ordinary shares at an exercise price of $37.18 expiring on December 12, 2027, another 45,000 at $62.17 expiring on December 11, 2028, 27,000 at $108.00 expiring on December 10, 2029, 22,755 at $176.28 expiring on December 10, 2030, and 14,504 at $139.65 expiring on December 9, 2031. These warrants are fully vested and currently exercisable. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, which vest beginning on March 1, 2027, and 2,517 ordinary shares outright. Each ordinary share is represented by one ADS.
Ascendis Pharma A/S executive Michael Wolff Jensen has filed a Form 3 detailing his equity-based holdings in the company. As EVP and Chief Legal Officer, he reports fully vested, currently exercisable warrants over 30,000 ordinary shares at an exercise price of 62.1700 per share, additional warrants over 27,000 shares at 108.0000, 22,755 shares at 176.2800, and 14,504 shares at 139.6500, all held directly.
He also reports restricted stock units representing 4,246, 3,197 and 9,552 ordinary shares. According to the footnotes, one RSU grant vests on March 1, 2027 with no expiration date, while other grants vest in two or three equal annual installments beginning on March 1, 2027. Each restricted stock unit corresponds to a contingent right to receive one ADS.
Ascendis Pharma A/S executive Mads Bodenhoff, SVP & PAO, reports existing equity-based holdings in the company. He holds warrants over 30,000, 3,117 and 3,687 underlying ordinary shares with exercise prices of 124.5200, 139.6500 and 110.0000, expiring between July 13, 2031 and October 11, 2032, with at least one warrant grant fully vested and currently exercisable.
He also holds restricted stock units covering 2,634, 3,967 and 2,768 underlying ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest on or beginning March 1, 2027, with some grants vesting in two or three equal annual installments and having no expiration date.
Ascendis Pharma A/S executive Anni Lotte Kirstine Sonderbjerg Pedersen has filed an initial Form 3 detailing her equity holdings. She directly owns 19,460 Ordinary Shares. In addition, she holds several series of fully vested, currently exercisable warrants over 20,000, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares with exercise prices ranging from 37.1800 to 176.2800 and expirations between 2027 and 2031.
She also holds Restricted Stock Units over 4,246, 6,394 and 9,552 underlying Ordinary Shares. Footnotes state that certain RSUs vest on March 1, 2027, with others vesting in two or three equal annual installments beginning on that date, and each RSU represents a contingent right to receive one American Depositary Share, with each ADS representing one Ordinary Share. The filing reports holdings only, with no purchases or sales.
Ascendis Pharma A/S director Lisa Morrison filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units tied to ordinary shares and American Depositary Shares. She holds 1,572 ordinary shares directly, fully vested warrants over multiple strike prices, and several RSU awards that begin vesting on March 1, 2027.
Ascendis Pharma A/S director Lars Holtug has filed an initial statement of beneficial ownership, detailing his equity interests in the company. He reports direct holdings of 4,236 Ordinary Shares, which may be held as American Depositary Shares where each ADS represents one Ordinary Share.
Holtug also holds warrants over 35,000, 7,500, 6,420 and 3,053 underlying Ordinary Shares at exercise prices of 61.0000, 108.0000, 176.2800 and 139.6500 respectively, expiring between November 13, 2028 and December 9, 2031. The warrants are fully vested and currently exercisable.
In addition, he holds restricted stock units covering 1,374, 2,070 and 1,930 underlying Ordinary Shares, each RSU representing a contingent right to receive one ADS. These RSUs vest beginning on March 1, 2027, with some vesting entirely on that date and others in two or three equal annual installments thereafter.
Ascendis Pharma A/S officer SPROGOE KENNETT filed an initial Form 3 showing existing equity holdings, rather than new transactions. The filing lists fully vested and currently exercisable warrants over 5,313, 45,000, 27,000, 22,755 and 14,504 Ordinary Shares at exercise prices of $37.18, $62.17, $108.00, $176.28 and $139.65 per share, respectively. It also reports three blocks of restricted stock units covering 4,246, 3,197 and 9,552 Ordinary Shares, which vest beginning on March 1, 2027 in one‑, two‑ and three‑year installment schedules and have no expiration date. In addition, the officer holds 19,460 Ordinary Shares directly and 110 Ordinary Shares indirectly through children. The footnotes clarify that each restricted stock unit corresponds to a right to receive one American Depositary Share, and each ADS represents one Ordinary Share.